¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Research communications in substance abuse."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gray substance
    ȸ»öÁú, ȸ¹éÁú
  • ground substance
    ¹ÙÅÁÁú, ±âÀú¹°Áú, ±âÁú
  • horny substance
    °¢Áú
  • intercellular cement substance
    ¼¼Æ÷»çÀÌÁ¢ÇÕÁú, ¼¼Æ÷°£Á¢ÇÕÁú
  • intercellular substance
    ¼¼Æ÷»çÀ̹°Áú, ¼¼Æ÷°£¹°Áú
  • metachromatic substance
    ÀÌ¿°»ö¹°Áú, ÀÌ¿°¼º¹°Áú(ì¶æøàõÚªòõ)
  • Nissl substance
    ´Ï½½¹°Áú
  • odoriferous substance
    Çâ·á
  • posterior perforated substance
    µÚ°üÅëÁú, ÈİüÅëÁú
  • pressor substance
    Ç÷¾Ð»ó½Â¹°Áú
  • paramagnetic substance
    »óÀÚ¼º¹°Áú
  • periaqueductal gray substance
    ¼öµµ°üÁÖÀ§È¸»öÁú, ¼ö°üÁÖÀ§È¸»öÁú
  • reducing substance
    ȯ¿ø¹°Áú
  • reticular substance
    ±×¹°±¸¼º¹°Áú, ¸Á»óü
  • radioactive substance
    ¹æ»ç¼º¹°Áú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú
  • carcinogenic substance
    ¹ß¾Ï¹°Áú
  • cement substance
    Á¢ÇÕÁú
  • chromophil substance
    (¢¡Nissl body) ´Ö½½¼Òü
  • compact substance
    Ä¡¹ÐÁú
  • conjugated estrogenic substance
    Á¢ÇÕ¹ßÁ¤¹°Áú
  • cortical substance
    °ÑÁú, ÇÇÁú
  • crystalline substance
    °áÁ¤¹°Áú
  • depressor substance
    °¨¾Ð¹°Áú, ³»¸²¹°Áú
  • endobiotic substance
    ³»¼º¹°Áú
  • enzyme trace substance theory
    È¿¼ÒÈçÀû¹°¼³
  • erythrocyte sensitizing substance
    ÀûÇ÷±¸¹Î°¨¹°Áú
  • exophthalmos-producing substance
    ´«µ¹ÃâÀ¯¹ß¹°Áú
  • ferromagnetic substance
    ¼¾ÀÚ¼º¹°Áú, °­ÀÚ¼ºÃ¼
  • fibrinoid substance
    ¼¶À¯¼Ò¼º¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antiketogenic substance
    Ç×ÄÉÅæ»ý¼º¹°Áú.
  • antimold (substance)
    Ç×°õÆÎÀÌ(¹°Áú).
  • antithyroid substance
    Ç×°©»ó¼±¹°Áú.
  • antiyeast substance
    Ç×È¿¸ð¹°Áú.
  • gelatinous substance
    ¾ÆaÁú, a¾çÁú(ÎïåÆòõ).
  • gelatinous substance
    ¾Æ±³Áú
  • gray substance
    ȸ»öÁú.
  • ground substance
    ±âÀú¹°Áú(Ðñî¼Úªòõ), ±âÁú(Ðñòõ).
  • heparinoid substance
    ÇìÆÄ¸°¾ç¹°Áú.
  • heterogeneous substance
    ºÒ±ÕÁúü.
  • horny substance
    °¢Áú(ÊÇòõ).
  • pneumococcal C-substance
    Æó·Å±¸±Õ C-¹°Áú
  • postacrosomal substance
    ÷´ÜüµÚ¹°Áú
  • posterior perforated substance
    µÚ°üÅëÁú
  • posterior perforated substance ³ª substantia perforata posterior
    ÈÄÀ¯°øÁú(ý­êóÍîòõ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • sexual abuse
    ¼ºÀûÇдë
  • spouse abuse
    ¹è¿ìÀÚÇдë(ùËÓâ)
  • voice abuse
    À½¼º³²¿ë, ¹ß¼º³²¿ë
  • accelerans substance
    ÃËÁø¹°Áú(õµòäÚªòõ).
  • accessory food substance
    ºÎ¿µ¾ç¹°(Üùç½å×Úª).
  • acrosomal substance
    ÷´Üü¹°Áú
  • agglutinable substance
    ÀÀÁý¼º ¹°Áú(ëêó¢àõÚªòõ).
  • anterior perforated substance
    ¾Õ°üÅëÁú
  • anterior pituitary-like substance
    ³úÇϼöü Àü¿±À¯»ç¹°Áú(¡­×¾ÞÄÚªòõ).
  • antibacterial substance
    Ç×±Õ¹°Áú.
  • antifungal substance
    Ç×Áø±Õ¼º ¹°Áú.
  • antifungal substance
    Ç×Áø±Õ¼º ¹°Áú.
  • antiketogenic substance
    Ç×ÄÉÅæ»ý¼º¹°Áú.
  • antimold (substance)
    Ç×°õÆÎÀÌ(¹°Áú).
  • antithyroid substance
    Ç×°©»ó¼±¹°Áú.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Osteoid substance
    Dz»À¹°Áú
    [¿¾ ¿ë¾î] °ñ¾çÁú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ERF Education and Research Foundation; external rotation in flexion; Eye Research Foundation
ICR [distance between] iliac crests; Institute for Cancer Research; Institute for Cancer Research [mouse...
ISR information storage and retrieval; Institute for Sex Research; Institute of Surgical Research; insul...
OHR occupational health research; Office of Health Research
AA/AD alcohol abuse/alcohol dependence
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
NIAAA National Institute of Alcohol Abuse and Alcoholism
NIDA National Institute of Drug Abuse
125I-BHSP 125I-Bolton Hunter substance P
TBARS 2-thiobarbituric acid-reacting substance
ARCI Addiction Research Center Inventory
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lateral intermediate substance
    °¡ÂÊ Áß°£ ȸ»öÁú
  • lens substance
    ¼öÁ¤Ã¼ ¹°Áú, ¼öÁ¤Ã¼ Áú
  • medullary substance
    ¼öÁú
    Ãà»è°ú ¼öÃʸ¦ ÀÌ·ç´Â ÁßÃ߽Űæ°èÀÇ ¹éÁú. ±â°ü ³»ºÎÀÇ À¯¿¬ÇÑ °ñ¼ö¾ç ¹°Áú.
  • nutrient substance
    ¿µ¾ç ¹°Áú
  • odoriferous substance
    Çâ·á
  • osteoid substance
    Dz »À ¹°Áú
  • pain producing substance
    µ¿Åë À¯¹ß ¹°Áú
  • psychoactive substance-induced organic mental disorder
    ȰÁ¤½Å¼º ¹°Áú·Î À¯µµµÈ ±âÁúÀû Á¤½Å Àå¾Ö
    ȰÁ¤½Å¼º ¹°ÁúÀÇ »ç¿ë°ú °ü·ÃµÈ ±âÁúÀû ³ú ÁõÈÄ. ¿­ °¡Áö Ư¼ö ÁõÈĸ¦ Æ÷ÇÔÇϰí Àִµ¥ Áßµ¶, Áß´Ü Áõ»ó, ¼¶¸Á, Ä¡¸Å, °Ç¸Á Àå¾Ö, ¸Á»ó Àå¾Ö, ȯ°¢, °¨Á¤ Àå¾Ö, Áö°¢ Àå¾Ö ¹× ÀÎ°Ý Àå¾Ö µîÀÌ´Ù. ¾ËÄÝ Áßµ¶°ú °°ÀÌ ¿øÀÎ ¹°ÁúÀÌ ¾Ë·ÁÁ® ÀÖÀ¸¸é À̸¦ ¸í±âÇÑ´Ù.
  • radioactive substance
    ¹æ»ç¼º ¹°Áú
  • receptive substance
    ¼ö¿ë ¹°Áú
    ±ÙÀ° Á¶Á÷, ƯÈ÷ ½Å°æÀÇ ¿îµ¿ Á¾ÆÇ ±Ùó¿¡ ÀÖÀ¸¸ç ÈïºÐÀ» ÀüµµÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ´Â ¹°Áú.
  • slow-reating substance
    Áö¹ÝÀÀ¼º ¹°Áú
    ¾î¶² ÆòȰ±ÙÀÇ ´À¸®°í Áö¼Ó¼ºÀÎ ¼öÃàÀ» ÀÏÀ¸Å°´Â ¾Æ³ªÇʶô½Ã ¹ÝÀÀ ½Ã¿¡ ¹æÃâµÇ´Â ¹°Áú ±âÈ£ SRS-A.
  • substance defect
    ¹°Áú °áÇÌ
  • substance P fiber
    P ¹°Áú ¼¶À¯
  • toxic substance
    À¯µ¶ ¼ººÐ, µ¶¹°
  • transmitter substance
    Àü´Þ ¹°Áú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
nursing administration research research concerned with establishing costs of nursing care, examining the relationships between nursing services and quality patient care, and viewing problems of nursing service delivery within the broader context of policy analysis and delivery of health services
(12 Dec 1998)
nursing education research Investigations into the problems of integrating research findings into nursing curricula, developing problem solving skills, finding approaches to clinical teaching, determining the level of practice by graduates from different basic preparations, etc.
(12 Dec 1998)
nursing evaluation research Research carried out by nurses that uses interviews, data collection, observation, surveys, etc., to evaluate nursing, health, clinical, and nursing education programs and curricula, and which also demonstrates the value of such evaluation.
(12 Dec 1998)
nursing methodology research Research carried out by nurses concerning techniques and methods to implement projects and to document information, including methods of interviewing patients, collecting data, and forming inferences. The concept includes exploration of methodological issues such as human subjectivity and human experience.
(12 Dec 1998)
nursing research Research carried out by nurses, generally in clinical settings, in the areas of clinical practice, evaluation, nursing education, nursing administration, and methodology.
(12 Dec 1998)
dental research The study of laws, theories, and hypotheses through a systematic examination of pertinent facts and their interpretation in the field of dentistry.
(12 Dec 1998)
operations research A group of techniques developed to apply scientific methods and tools to solve the problems of decision making in complex organizations and systems. Operations research searches for optimal solutions in situations of conflicting goals and makes use of mathematical models from which solutions for actual problems may be derived.
(12 Dec 1998)
epidemiologic research design The form and structure of analytic studies in epidemiologic and clinical research.
(12 Dec 1998)
united states agency for health care policy and research An agency of the public health service established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery.." it supersedes the national centre for health services research.
(12 Dec 1998)
united states office of research integrity An office of the united states public health service organised in june 1992 to promote research integrity and investigate misconduct in research supported by the public health service. It consolidates the office of scientific integrity of the national institutes of health and the office of scientific integrity review in the office of the assistant secretary for health. The ori is in the office of the assistant secretary for health and its director reports directly to the assistant secretary for health, department of health and human services. (ri newsletter, 1993 jan; 1(1):1)
(12 Dec 1998)
alpha substance A filamentous plasmatic material, beaded with granules, demonstrable by means of vital staining in the immature red blood cells.
Synonym: alpha substance, filar mass, filar substance, substantia reticularis, substantia reticulofilamentosa.
Synonym: reticular formation.
(05 Mar 2000)
anterior perforated substance A region at the base of the brain through which numerous small branches of the anterior and middle cerebral arteries (lenticulostriate arteries) enter the depth of the cerebral hemisphere; it is bordered medially by the optic chasm and anterior half of the optic tract, rostrally and laterally by the lateral olfactory stria; its anteromedial part corresponds to the olfactory tubercle.
Synonym: substantia perforata anterior, locus perforatus anticus, olfactory area.
(05 Mar 2000)
autacoid substance A substance formed metabolically by one set of cells, which alters the function of other cells. (This term is sometimes used in place of the term hormone.)
(05 Mar 2000)
bacteriotropic substance Opsonin or other substance that alters bacterial cells in such a manner that they are more susceptible to phagocytic action.
(05 Mar 2000)
basophilic substance The material consisting of granular endoplasmic reticulum and ribosomes that occurs in nerve cell bodies and dendrites.
Synonym: basophil substance, basophilic substance, chromophil substance, Nissl bodies, Nissl granules, substantia basophilia, tigroid bodies, tigroid substance.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á